FINWIRES · TerminalLIVE
FINWIRES

瑞銀預計加拿大央行下週將維持利率不變,但已做好應對準備。

-- 瑞銀表示,鑑於經濟前景的不確定性,預計加拿大央行將在下週三的4月會議上維持利率不變,並維持利率不變至今年底。 瑞銀在致客戶的報告中指出,貿易緊張局勢和人工智慧技術顛覆帶來的風險依然存在,而中東局勢的前景也充滿不確定性。 瑞銀表示,最新的加拿大經濟數據「喜憂參半」。 3月能源價格推高了整體通膨,核心通膨有所緩和,勞動市場仍低迷。加拿大央行的最新調查顯示,短期通膨預期略有上升,但瑞銀預測,長期通膨預期的相對穩定使得4月的利率前景依然具有很大的靈活性。 瑞銀預測,加拿大央行將繼續發出訊號,顯示經濟前景存在許多風險,但政策制定者已做好隨時應對的準備。 瑞銀補充道,週三的新聞發布會可能會重點討論3月份總體通膨走強而核心通膨放緩所帶來的通膨風險。 瑞銀認為,通膨風險與喜憂參半的經濟活動和勞動市場數據的平衡也可能成為關注焦點。鑑於最新季度調查中通膨預期的變化,加拿大央行行長蒂夫·麥克勒姆可能會在其準備好的演講中指出,或者在問答環節中提及,通膨預期的錨定是加拿大央行能夠克服能源價格上漲帶來的通膨影響的重要因素。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703